当前位置: X-MOL 学术Lancet Respir. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative?
The Lancet Respiratory Medicine ( IF 76.2 ) Pub Date : 2019-11-12 , DOI: 10.1016/s2213-2600(19)30363-7
Lindsay McKenna 1 , Jennifer Furin 2
Affiliation  

Around 10 million people become sick with tuberculosis, and more than 1·2 million people die from the disease each year. WHO has proposed some ambitious targets in their End TB Strategy, and global leaders committed to reaching these targets within the next decade. As these deadlines approach, the rhetoric has increased but has produced seemingly little progress, creating an air of desperation among all cadres engaged in the fight against tuberculosis.

中文翻译:

含有类前manmanid的结核病治疗是胜利还是胜利的叙事?

每年约有1000万人患有结核病,每年死于该病的人数超过1·200万人。世卫组织在其“结核病最终防治战略”中提出了一些雄心勃勃的目标,全球领导人承诺在未来十年内实现这些目标。随着这些截止日期的临近,言辞增加了,但进展甚微,在所有与结核病作斗争的干部中产生了绝望的气氛。
更新日期:2019-11-26
down
wechat
bug